Unknown Author

Illumina shares stumbled 10% following its earnings report, confusing investors who saw a clear revenue beat. However, valuation models suggest this selloff is a buying opportunity, projecting a path to $184 as the company's clinical business accelerates.

A "sell the news" reaction sent Qualys crashing 13%, even after the company delivered a solid earnings beat. However, fundamental models suggest the selling is overdone, pointing to a $149 fair value that implies significant upside for patient investors.

Amphenol's AI data center boom drives 106% stock surge. With record orders and CommScope acquisition, can APH stock reach $193 by 2028?